ENLV

Enlivex Announces Second Quarter 2021 Financial Results and Provides a Business Update

Enlivex Hires Biotech Industry Veteran Tzvi Palash to Lead the Design and Construction of its New cGMP Allocetra Manufacturing Plant

Enlivex: Interesting Macrophage Reprogramming Science Targets $33B Sepsis Market

Enlivex To Study Allocetra Combined With Checkpoint Inhibitors In Solid Tumor Settings

Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors

Enlivex Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis and GvHD Using Allocetra Immunotherapy

Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares